Initiation of a formalized precision medicine program in gynecologic oncology
详细信息 查看全文
- 作者：Camille C. Gunderson ; camille-gunderson@ouhsc.edu" class="auth_mail" title="E-mail the corresponding author ; Michelle R. Rowland michelle-rowland@ouhsc.edu" class="auth_mail" title="E-mail the corresponding author ; Deborah L. Wright deborah-wright@ouhsc.edu" class="auth_mail" title="E-mail the corresponding author ; Kelsi L. Andrade kelsi-andrade@ouhsc.edu" class="auth_mail" title="E-mail the corresponding author ; Robert S. Mannel robert-mannel@ouhsc.edu" class="auth_mail" title="E-mail the corresponding author ; D. Scott McMeekin scott-mcmeekin@ouhsc.edu" class="auth_mail" title="E-mail the corresponding author ; Kathleen N. Moore kathleen-moore@ouhsc.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Precision medicine ; Variants of known significance ; Genomic alterations ; Actionable mutations
- 刊名：Gynecologic Oncology
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：141
- 期：1
- 页码：24-28
- 全文大小：425 K
文摘
- •
Precision medicine enables individualized therapy for gynecologic oncology patients.
- •
Genomic profiling and continued drug development are necessary to offer targeted therapies.
- •
Gynecologic cancers typically have low rates of actionable mutations.